MIFlowCyt: The Minimum Information about a Flow Cytometry Experiment

doi:10.1002/cyto.a.20623

Cytometry A. Author manuscript; available in PMC 2009 November 5.

Published in final edited form as:

Cytometry A. 2008 October; 73(10): 926–930.

doi: 10.1002/cyto.a.20623

PMCID: PMC2773297

NIHMSID: NIHMS76346

MIFlowCyt: The Minimum Information about a Flow Cytometry Experiment

Jamie A. Lee,^* Josef Spidlen,^† Keith Boyce,^‡ Jennifer Cai,^* Nicholas Crosbie,^§ Mark Dalphin,^¶ Jeff Furlong,^|| Maura Gasparetto,^† Michael Goldberg,^# Elizabeth M. Goralczyk,^** Bill Hyun,^†† Kirstin Jansen,^|| Tobias Kollmann,^‡‡ Megan Kong,^* Robert Leif,^§§ Shannon McWeeney,^¶¶ Thomas D. Moloshok,^** Wayne Moore,^|||| Garry Nolan,^## John Nolan,^*** Janko Nikolich-Zugich,^††† David Parrish,^‡ Barclay Purcell,^‡‡‡ Yu Qian,^* Biruntha Selvaraj,^‡‡‡ Clayton Smith,^† Olga Tchuvatkina,^# Anne Wertheimer,^§§§ Peter Wilkinson,^¶¶¶ Christopher Wilson,^|| James Wood,^|||||| Robert Zigon,^### the International Society for Analytical Cytology Data Standards Task Force, Richard H. Scheuermann,^*^****; and Ryan R. Brinkman^†

^* Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

^† Terry Fox Laboratory, BC Cancer Agency, Vancouver, V5Z 1L3, BC, Canada

^‡ Immune Tolerance Network, Pittsburgh, PA 15238, USA

^§ Inivai Technologies, Mentone 3194, Victoria, Australia

^¶ Amgen Inc., Thousand Oaks, CA 91320, USA

^|| Department of Immunology, University of Washington, Seattle, WA 98195, USA

^# BD Biosciences, San Jose, CA 95131, USA

^** Fox Chase Cancer Center, Philadelphia, PA 19111, USA

^†† Laboratory for Cell Analysis, University of California, San Francisco, CA 94143-0808, USA

^‡‡ Vaccine Evaluation Center, Child & Family Research Institute, Department of Pediatrics, University of British Columbia, Vancouver, V5Z 4H4, BC, Canada

^§§ Newport Instruments, San Diego, CA 92115, USA

^¶¶ OHSU Cancer Institute; Division of Biostatistics, Department of Public Health and Preventive Medicine; Oregon Clinical and Translational Research Institute; Oregon Health and Science University, Portland, OR 97006, USA

^|||| Genetics Department, Stanford University School of Medicine, Stanford, CA 94305, USA

^## Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA

^*** La Jolla Bioengineering Institute, La Jolla, CA 92037, USA

^††† Department of Molecular Microbiology and Immunology, Vaccine & Gene Therapy Institute and, Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR 97006, USA

^‡‡‡ Cytopeia Incorporated, Seattle, WA 98125, USA

^§§§ Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR 97006, USA

^¶¶¶ University of Montreal, Montreal, QC, H3C 3J7, Canada

^|||||| Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA

^### Beckman Coulter, Inc., 7451 Winton Drive, Indianapolis, IN USA

^**** Division of Biomedical Informatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Corresponding author. Email: rbrinkman/at/bccrc.ca

JAL and JS contributed equally to the work in this article

The publisher's final edited version of this article is available free at Cytometry A

See other articles in PMC that cite the published article.

Abstract

Background

A fundamental tenet of scientific research is that published results are open to independent validation and refutation. Minimum data standards aid data providers, users and publishers by providing a specification of what is required to unambiguously interpret experimental findings. Here, we present the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) standard, stating the minimum information required to report flow cytometry (FCM) experiments.

Methods

We brought together a cross-disciplinary international collaborative group of bioinformaticians, computational statisticians, software developers, instrument manufacturers, and clinical and basic research scientists to develop the standard. The standard was subsequently vetted by the International Society for the Advancement of Cytometry (ISAC) Data Standards Task Force, Standards Committee, membership and Council.

Results

The MIFlowCyt standard includes recommendations about descriptions of the specimens and reagents included in the FCM experiment, the configuration of the instrument used to perform the assays and the data processing approaches used to interpret the primary output data.

MIFlowCyt has been adopted as a standard by ISAC, representing the flow cytometry scientific community including scientists as well as software and hardware manufactures.

Conclusions

MIFlowCyt’s adoption by the scientific and publishing communities will facilitate third-party understanding and reuse of flow cytometry data.

Keywords: immunology, fluorescence-activated cell sorting, knowledge representation

Introduction

Flow cytometry systems have been available to investigators for over 30 years, and the field continues to advance at a rapid rate. Flow cytometry has been responsible for major progress in basic and clinical research by enabling the phenotypic and functional characterization of individual cells in a high-throughput manner. Advances in the technology now allow for automated, multi-parametric analyses of thousands of samples per day (1). Each data set can consist of multi-dimensional descriptions of millions of individual cells, producing data similar in size and complexity to gene expression microarrays. Like the microarray field, the ability to collect flow cytometry data is outpacing the computational means for data handling and analysis. Furthermore, the lack of reporting standardization limits collaboration, independent validation/refutation and meta-analysis, and thus minimizes the value of the wealth of existing flow cytometry data due to poor annotation (2). Such technological advances, in the absence of reporting standards, also introduce considerable challenges for the producers, reviewers, and consumers of today’s biomedical and immunology literature (3).

To address these shortcomings, we have brought together a cross-disciplinary international collaborative group of bioinformaticians, computational statisticians, software developers, instrument manufacturers, and clinical and basic research scientists to develop a minimum information reporting standard for flow cytometry. This large collaborative group proposed the initial version of the “Minimum Information about a Flow Cytometry Experiment” (MIFlowCyt). The proposal underwent several stages of consultations by the International Society for Analytical Cytology (ISAC) Data Standards Task Force (DSTF), which has been responsible for all flow cytometry-related standards for the past 30 years, such as the FCS (4) data file standard. MIFlowCyt was further reviewed by the broader scientific community and finally approved by the ISAC DSTF, ISAC Data Standards Committee and, recently adopted as an ISAC standard by the ISAC Council. MIFlowCyt is also endorsed by the Data Interoperability Steering Committee (DISC) of the Division of Allergy, Immunology and Transplantation (DAIT) within the National Institute of Allergy and Infectious Diseases (NIAID), which strongly supports the use of MIFlowCyt and related data format standards.

Results

Design Principles

Throughout the biomedical sciences, minimum information checklists are beginning to find favor with scientists, publishers and funders alike. Such checklists ensure that descriptions of methods, resulting data and analyses support the unambiguous interpretation, corroboration and reuse of data (5). As emphasized by several cross-community integration efforts, e.g., FuGE (6), MIBBI (5), OBI (7), most biological and biomedical investigations have similar design patterns. Typically, they are driven by a hypothesis or purpose, which guides the experimental design. Samples or specimens are prepared and reagents are used to evaluate analytes within the samples. Data are acquired using instruments, followed by data processing and analysis to interpret and conclude the experiment.

In order to simplify cross-domain comparison and integration, the required minimum information specified by MIFlowCyt (see Supplementary material) is organized similarly to minimal information requirements for other MIBBI-registered high-throughput biological experiments, i.e., organizing the information by experiment overview, sample/specimen description, instrument details, and data analysis (Table 1). The organization of MIFlowCyt does not specify the order or format in which experiment annotation should be provided, and MIFlowCyt is not intended to replace any additional information already collected within any particular group. The actual information is expected to come from several sources. Research scientists provide detailed information about the experiment overview and design, information about the samples used in the experiment including preparation, treatment, and staining details, and details about data analysis procedures. Flow cytometry instruments are expected to provide details about configuration and settings and analytical software details relevant to performed analyses. An example of a MIFlowCyt-compliant experiment annotation is provided as Supplementary material.

Table 1

Components of a MIFlowCyt-compliant experiment description. To simplify cross-platform comparison and integration, MIFlowCyt is organized in a similar way to minimal information standards from other technological domains.

MIFlowCyt is explicit in its requirements, following constraint and design recommendations from professional standardization bodies (e.g., http://www.ietf.org/rfc/rfc2119.txt; http://standards.ieee.org/guides/style/). The word shall is used to indicate that a particular item is an absolute requirement of the specification. It identifies information that is absolutely crucial in order to allow for interpretation of the experiment. Shall combined with if relevant indicates information that is not generally applicable but could impact the interpretation of a particular experiment in certain cases. The word should is used to indicate that a particular item is recommended but not required. The normative version of this standard is available as supplemental information to this manuscript. The key design considerations for MIFlowCyt are described below.

Experiment Overview

An experiment is the evaluation of a set of one or more samples with a specific purpose or objective, such as testing a hypothesis or diagnosing a patient. Information about the overall experiment design shall be provided in order to understand specific experiment details in the proper context. These details shall include a brief description of the purpose of the experiment and a summary of findings including the interpretation of the results or outcomes. It shall be supported by a list of keywords, preferably from a controlled vocabulary (such as MeSH, http://www.nlm.nih.gov/mesh/), to facilitate quick orientation and cross-experiment comparison.

If relevant, details shall be provided about experimental variables, i.e. attributes that differ between samples within an experiment due to pre-existing differences in sample states (conditional variables) or due to experimental manipulation of the samples (manipulated variables), as they are important in understanding the relationship between samples within the experiment (e.g., smoker versus nonsmoker).

Quality control measures (e.g., replicates, calibrations, or control assays) shall be described to support comparative statistical evaluation.

Contact information shall be included for further information requests.

Flow Sample/Specimen Description

Description of the sample (or specimen as commonly used in the clinical domain) material and its preparation, treatment, and evaluation are crucial for understanding the experiment. MIFlowCyt specifies three types of samples: biological, environmental, and other samples. For all sample types, a description of the sample shall include information about the nature of the sample material (such as peripheral blood, seawater, or dyed plastic beads). For biological samples, a description of the source shall be provided (e.g., blood as the source of mononuclear cells) and the organism from which they were originally derived shall be identified. Ontologies and/or standardized vocabularies, such as NCBI taxonomy (http://www.ncbi.nlm.nih.gov/Taxonomy) should be used to facilitate correct interpretation.

Sample treatment descriptions shall specify treatment agents and conditions essential for experiment interpretation or cross-experiment querying, comparisons, and analyses. Access to information about the reagents and how they were used is critical for the correct interpretation of data. Reagents in a flow cytometry experiment are conceptually similar to reagents used in other experiment types: they serve the purpose of measuring analytes and have analyte detector and reporter components. In a flow cytometry experiment, the analyte is often a cell surface protein (e.g., CD25), the analyte detector is often an antibody (e.g., anti-CD25) that specifically binds the analyte, and the reporter is typically a fluorochrome (e.g., FITC).

A description of the entity(ies), disposition(s), or process(es) being evaluated (e.g., CD25, apoptosis, membrane permeability) shall be provided whenever there is ambiguity about the analyte that is being measured by the reagent. For example, if propidium iodide (PI) is added to permeabilized cells, it binds to DNA and thus measures DNA content (e.g., for the evaluation of cell cycle status). When PI is added to non-permeabilized cells, it is taken up selectively by membrane-compromised cells and is thus an indicator of membrane integrity and cell viability. This is an example of a single reagent measuring different attributes depending on the conditions used for the preparation of the experiment sample, which illustrates the importance of capturing these details.

Instrument Details

Flow cytometers generally consist of three major subsystems: fluidic, optical and electronic. Flow cytometers operate by passing a sample-containing fluid stream through a beam of light of a specific wavelength. The scattered and emitted fluorescent light is then collected and transformed to electrical signals, involving a combination of optical and electronic components such as lenses, filters, mirrors, beam splitters, and detectors. The instrument and its configuration and settings directly affect the resulting data. Therefore, it is essential to capture detailed descriptions of selected components of cytometer subsystems in order to properly interpret experimental results.

The instrument manufacturer and model number shall be sufficient if these uniquely specify the required instrument components. Details listed in this section are only required for user-configurable components and cases in which the make and model number are not sufficient to identify the required information. Providing all of the required instrumentation details for configurable components may seem tedious however, most of these are expected to be provided by instrument manufactures and the instruments themselves.

The fundamental information linking sample characteristics to data includes excitation wavelengths of light sources and wavelengths passed by each of the filters. However, it has been demonstrated that other details are also critical (8, 9). For example, fluorochrome excitation depends on laser power, material degradation over time influences the performance of optical filters, photomultiplier tube gain highly depends on voltage settings, etc. The amount of light, polarization, and the beam size where the particle is interrogated depend significantly on the optics used to transmit the light from its source to the flow cell component of the fluidics subsystem. The amount of light reaching the flow cell is dependent on the number of optical surfaces involved, the optical coatings used, and the efficiency of any optical fibers used. Thus, the type of flow cell shall be specified as it can affect sensitivity by impacting the background and laser power requirements (10). Specification of the full optical path shall include specification of the light source(s) and the enumeration of all optical components (e.g., optical filters, beam splitters, mirrors, etc.), shall specify the detector used and shall state the characteristic of the signal (e.g., height, width, or area) that is being digitalized into the parameter value.

Data Analysis

A fundamental principle guiding the publication of scientific results is that supporting data must be made available in a form that allows for independent evaluation of the conclusions as reflected in the data and materials availability policies in most journals (11, 12). A common raw data output of a flow cytometry experiment is a list mode data file, e.g., FCS (4). Ideally, a list mode data file contains the set of measured parameters (e.g., fluorescence intensities) for each event (e.g., a cell) collected in the sample. These data are crucial for independent re-analysis, therefore they shall either be provided directly or details shall be stated on how they may be requested.

Fluorescence compensation is a data transformation process used to subtract the fluorescence signal due to one fluorochrome from the fluorescence signal due to another fluorochrome when the fluorochromes have overlapping emissions spectra. Compensation can be performed after signal detection but before digitalization (“hardware compensation”), or after the data have been collected (“software compensation”). Mathematically, compensation is a straightforward application of linear algebra describable by a compensation matrix, which is often part of the FCS data files. The type of compensation shall be described (e.g., no compensation, hardware compensation, computed compensation) and the spillover or compensation matrix shall be provided whenever available.

Typically, flow cytometry data are analyzed in the context of gates. Gating is a data filtering process by which populations of events are defined based on parameter value subset combinations. Gating descriptions shall be clear and unambiguous, preferably by mathematical descriptions of each gate boundary. It is important to define qualitative gate descriptors as well as to state denominators used to calculate percentages of events within a gate. The overall gating strategy shall be traceable up to the set of all events.

Discussion

The importance of minimal data reporting standards is illustrated by both community-driven standards such as MIAME (13), MIRIAM (14), MISFISHIE (15), and the CONSORT checklist (16), and cross-community efforts including MIBBI (5), FuGE (6), and OBI (7). MIFlowCyt fills a recognized gap in biomedical data reporting standards by outlining the minimum information required to interpret flow cytometry experiments, understand the conclusions reached, and make comparisons to experiments performed by different laboratories. Nebulous standards and guidelines lead to alternative interpretations resulting in non-uniform, inconsistent reporting (17). MIFlowCyt follows the minimal specification design and overall goals as specified by MIBBI, and clearly and explicitly identifies the minimum required information for reporting flow cytometry experiments. It communicates the minimum threshold for data exchange and study interpretation, enumerating all of the items required to be reported and the depth of required details. Through MIBBI, MIFlowCyt also aims to contribute to the development of a shared checklist focused on the common experiment components shared among all communities.

MFIowCyt represents the first crucial step in our efforts to develop universal solutions for representing, collecting, annotating, archiving, analyzing, and disseminating flow cytometry data. Such a minimum information standard sets the stage for the integration of data repositories and data analysis tools. MIFlowCyt describes the minimum information content required to interpret a flow cytometry experiment, independent of the form of how the information is provided. While specification of the form (i.e., data formats) is also essential to facilitate accurate exchange and reuse of experiment data and development of new analytical tools (17, 18), these needs are being addressed through separate, coordinated efforts (19, 20). For example, a specification for the provision of gating details in XML has been accepted by ISAC’s DSTF for consideration as the basis for an eventual standard (http://flowcyt.sourceforge.net). Adoption of MIFlowCyt and related standards by Laboratory Information Management Systems (LIMS) would ensure effective interoperability between investigators and other software applications

The development of MIFlowCyt has been coordinated with submission of applicable flow cytometry-specific terms into OBI and other related ontologies, enabling the potential for structured queries and automated data analysis. Through FICCS (The Flow Informatics and Computational Cytometry Society, http://www.ficcs.org), coordinated efforts have been initiated to develop a data model based on MIFlowCyt by extending FuGE. Publicly available flow cytometry data files are commonly attached as supplementary materials to publications – an unreliable method that does not preserve the data files (17). Therefore, as MIAME guidelines led to expansion of public microarray data repositories such as ArrayExpress (http://www.ebi.ac.uk/arrayexpress) and GEO (http://www.ncbi.nlm.nih.gov/geo), we expect MIFlowCyt to influence flow cytometry in a similar way. For example, the Immunology Database and Analysis Portal (http://www.immport.org) has adopted the MIFlowCyt framework for the capture of flow cytometry data from investigators funded by the Division of Allergy, Immunology and Transplantation of the NIAID. In addition, efforts are underway under the auspices of ISAC to develop a public data repository for flow cytometry data based on MIFlowCyt.

MIFlowCyt is an ISAC standard stating the minimum information required to report flow cytometry experiments. The normative version of this standard and an example of a MIFlowCyt-compliant experiment annotation are available as supplemental information to this manuscript and from http://www.isac-net.org/, http://flowcyt.sourceforge.net/, and http://mibbi.sourceforge.net/. Broad adoption of MIFlowCyt by research scientists, clinicians, instrument manufacturers, software developers, and publishers will foster scientific collaboration. It will preserve the integrity and quality of flow cytometry data, which will significantly contribute to the advancement of biomedical sciences by enabling scientists to build upon previous findings.

Supplementary Material

Supp Example

Click here to view.^{(396K, pdf)}

Supp Rec

Click here to view.^{(76K, pdf)}

Supp Summ

Click here to view.^{(19K, pdf)}

Acknowledgments

This work has been supported by the NIH grant EB005034 from the National Institute of Biomedical Imaging And Bioengineering and by the NIAID Bioinformatics Integration Support Contract AI40076 (BISC). RRB is a Michael Smith Foundation for Health Research Scholar and a ISAC Scholar. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Biomedical Imaging And Bioengineering or the National Institutes of Health. We would also like to thank the International Society for the Advancement of Cytometry, the Flow Informatics and Computational Cytometry Society, and the Data Interoperability Steering Committee of the Division of Allergy, Immunology and Transplantation within the National Institute of Allergy and Infectious Diseases for their support and contribution to this effort. Special thanks to James Wood for chairing the ISAC adoption process.

References

1. Gasparetto M, Gentry T, Sebti S, O’Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods. 2004;292:59–71. [PubMed]

2. Maecker HT, Rinfret A, D’Souza P, Darden J, Roig E, Landry C, Hayes P, Birungi J, Anzala O, Garcia M, Harari A, Frank I, Baydo R, Baker M, Holbrook J, Ottinger J, Lamoreaux L, Epling CL, Sinclair E, Suni MA, Punt K, Calarota S, El-Bahi S, Alter G, Maila H, Kuta E, Cox J, Gray C, Altfeld M, Nougarede N, Boyer J, Tussey L, Tobery T, Bredt B, Roederer M, Koup R, Maino VC, Weinhold K, Pantaleo G, Gilmour J, Horton H, Sekaly RP. Standardization of cytokine flow cytometry assays. BMC Immunol. 2005;6:13. [PMC free article] [PubMed]

3. Herzenberg LA, Tung J, Moore WA, Herzenberg LA, Parks DR. Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol. 2006;7:681–685. [PubMed]

4. Seamer LC, Bagwell CB, Barden L, Redelman D, Salzman GC, Wood JC, Murphy RF. Proposed new data file standard for flow cytometry, version FCS 3.0. Cytometry. 1997;28:118–122. [PubMed]

5. Taylor CF, Field D, Sansone S-A, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz P-A, Bogue M, Booth T, Brazma1 A, Brinkman RR, Clark AM, Deutsch EW, Fiehn O, Fostel J, Ghazal P, Gibson F, Gray T, Grimes G, Hardy NW, Hermjakob H, Julian RK, Jr, Kane M, Kettner C, Kinsinger C, Kolker E, Kuiper M, Le Novère N, Leebens-Mack J, Lewis SE, Lord P, Mallon A-M, Marthandan N, Masuya H, McNally R, Mehrle A, Morrison N, Quackenbush J, Reecy JM, Robertson DG, Rocca-Serra P, Rodriguez H, Santoyo-Lopez J, Scheuermann RH, Schober D, Smith B, Snape J, Tipton K, Sterk P, Wiemann S. Promoting Coherent Minimum Reporting Requirements for Biological and Biomedical Investigations: The MIBBI Project. Nat Biotechnol. 2007 (In Press)

6. Jones AR, Miller M, Aebersold R, Apweiler R, Ball CA, Brazma A, Degreef J, Hardy N, Hermjakob H, Hubbard SJ, Hussey P, Igra M, Jenkins H, Julian RK, Jr, Laursen K, Oliver SG, Paton NW, Sansone SA, Sarkans U, Stoeckert CJ, Jr, Taylor CF, Whetzel PL, White JA, Spellman P, Pizarro A. The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol. 2007;25:1127–1133. [PubMed]

7. Whetzel PL, Brinkman RR, Causton HC, Fan L, Field D, Fostel J, Fragoso G, Gray T, Heiskanen M, Hernandez-Boussard T, Morrison N, Parkinson H, Rocca-Serra P, Sansone SA, Schober D, Smith B, Stevens R, Stoeckert CJ, Jr, Taylor C, White J, Wood A. Development of FuGO: an ontology for functional genomics investigations. OMICS. 2006;10:199–204. [PMC free article] [PubMed]

8. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods. 2000;243:77–97. [PubMed]

9. Shapiro HM. 8 Buying Flow Cytometers, 9 Building flow cytometers. In: Doe JA, Doe B, Doe CD, editors. Practical Flow Cytometry. 4. Wiley-Liss; City, State abbr: 2003. pp. 411–442.

10. Shapiro HM. 4.6 How Flow Cytometers Work - Flow Systems. In: Doe JA, Doe B, Doe CD, editors. Practical Flow Cytometry. 4. Wiley-Liss; City, State abbr: 2006. pp. 166–180.

11. Ball CA, Brazma A, Causton H, Chervitz S, Edgar R, Hingamp P, Matese JC, Parkinson H, Quackenbush J, Ringwald M, Sansone S-A, Sherlock G, Spellman P, Stoeckert C, Tateno Y, Taylor R, White J, Winegarden N. Submission of microarray data to public repositories. PLoS Biol. 2004;2:E317. [PMC free article] [PubMed]

12. Bourne P. Will a biological database be different from a biological journal? PLoS Comput Biol. 2005;1:179–181. [PMC free article] [PubMed]

13. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29:365–371. [PubMed]

14. Le Novere N, Finney A, Hucka M, Bhalla US, Campagne F, Collado-Vides J, Crampin EJ, Halstead M, Klipp E, Mendes P, Nielsen P, Sauro H, Shapiro B, Snoep JL, Spence HD, Wanner BL. Minimum information requested in the annotation of biochemical models (MIRIAM) Nat Biotechnol. 2005;23:1509–1515. [PubMed]

15. Deutsch EW, Ball CA, Bova GS, Brazma A, Bumgarner RE, Campbell D, Causton HC, Christiansen J, Davidson D, Eichner LJ, Goo YA, Grimmond S, Henrich T, Johnson MH, Korb M, Mills JC, Oudes A, Parkinson HE, Pascal LE, Quackenbush J, Ramialison M, Ringwald M, Sansone SA, Sherlock G, Stoeckert CJ, Jr, Swedlow J, Taylor RC, Walashek L, Zhou Y, Liu AY, True LD. Development of the Minimum Information Specification for In Situ Hybridization and Immunohistochemistry Experiments (MISFISHIE) OMICS. 2006;10:205–208. [PubMed]

16. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust. 2006;185:263–267. [PubMed]

17. Burgoon LD. The need for standards, not guidelines, in biological data reporting and sharing. Nat Biotechnol. 2006;24:1369–1373. [PubMed]

18. Quackenbush J. Data standards for ‘omic’ science. Nat Biotechnol. 2004;22:613–614. [PubMed]

19. Spidlen J, Gentleman RC, Haaland PD, Langille M, Le Meur N, Ochs MF, Schmitt C, Smith CA, Treister AS, Brinkman RR. Data standards for flow cytometry. OMICS. 2006;10:209–214. [PMC free article] [PubMed]

20. Leif RC. CytometryML, a data standard, which has been designed to interface with other standards. SPIE BiOS. 2007:6441.